Coherus schedules November 9 results. Coherus Oncology stock gains 4.68 percent
Published on 10/27/2026 at 19:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSReporting date and price action
- Coherus Oncology will publish third-quarter 2026 results on November 9, 2026.
- Second-quarter 2026 revenue reached USD 14.31 million, versus USD 10.25 million a year earlier.
- Coherus Oncology stock costs EUR 0.94 at Lang & Schwarz on October 27, 2026 at 7:02 p.m. CET, 4.68 percent above the Tradegate close of October 26, 2026.
- Interim Tagmokitug data are scheduled for an October 28, 2026 webcast.
Coherus Oncology (US19249H1032) will publish third-quarter 2026 results on November 9, 2026, giving investors a scheduled checkpoint after second-quarter revenue reached USD 14.31 million. The announcement was issued by GlobeNewswire on October 26, 2026. At Lang & Schwarz, the stock was trading at EUR 0.94 on October 27, 2026 at 7:02 p.m. CET, up 4.68 percent versus the Tradegate close of October 26, 2026 at EUR 0.90.
November 9 sets the next test
The November 9 reporting date matters because Coherus is still operating from a relatively small revenue base. In the second quarter of 2026, revenue was USD 14.31 million, compared with USD 10.25 million in the second quarter of 2025, according to The Globe and Mail. That is a year-over-year increase of 39.61 percent. The same report cited a GAAP net loss of USD 20.63 million, versus USD 41.34 million a year earlier.
Coherus has also scheduled an interim Tagmokitug clinical-data webcast for October 28, 2026. The investor-relations page lists the event for 4:30 p.m. Eastern Daylight Time, while the company describes Tagmokitug as a Phase 1b antibody program in solid tumors.
Stock position and valuation
The euro quote sits above the October 26 Tradegate close, while the primary Nasdaq quote was USD 1.04 on October 27, 2026 at 2:02 p.m. EDT. The same market snapshot puts the 52-week Nasdaq range at USD 0.94 to USD 2.62, with market capitalization of USD 161.5 million and volume of 283,773 shares.
Coherus had a negative price-to-earnings ratio of -1.02 and no dividend yield in the October 27, 2026 quote. A September 22, 2026 report by The Globe and Mail said H.C. Wainwright reiterated a Buy rating and set a USD 7.00 price target.
Comparison with peers
Coherus Oncology: up 4.68 percent versus the Tradegate close, price-to-earnings ratio -1.02, market capitalization USD 161.5 million.
AbbVie (NYSE, USD): down 0.04 percent, price-to-earnings ratio 80.75, market capitalization USD 506.5 billion.
Amgen (Nasdaq, USD): up 0.54 percent, price-to-earnings ratio 27.75, market capitalization USD 241.7 billion.
Dates now shape the outlook
October 28, 2026 brings the Tagmokitug webcast, followed by the third-quarter results release and conference call on November 9, 2026. Those dates provide the next concrete reference points for clinical progress and revenue execution.
Coherus Oncology was trading at EUR 0.94 at Lang & Schwarz on October 27, 2026 at 7:02 p.m. CET, 4.68 percent above the Tradegate close of October 26, 2026 at EUR 0.90. The further course of trading is shown by the continuously updated real-time quote of Coherus Oncology stock.
Coherus Oncology at a glance
- Company: Coherus Oncology, Inc.
- ISIN: US19249H1032
- Ticker: CHRS
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 27, 2026, 7:02 p.m. CET): EUR 0.94
- Change versus Tradegate close: plus 4.68 percent
- Tradegate close (October 26, 2026): EUR 0.90
- Market capitalization: USD 161.5 million (as of October 27, 2026)
- 52-week range: USD 0.94-2.62 (as of October 27, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 9, 2026
Market context: Market report S&P 500.
